Mico Biomed, Public Offering Subscription Competition Rate 41.74 to 1... Listing on KOSDAQ on the 22nd

[Asia Economy Reporter Eunmo Koo] MikobioMed, a bio medical diagnostic company, announced on the 15th that the final subscription competition rate recorded 41.74 to 1 after conducting a public offering subscription for general investors over two days from the 13th to the 14th. The subscription deposit was estimated at approximately 156.5 billion KRW. MikobioMed is scheduled to be listed on the KOSDAQ market on the 22nd. Previously, MikobioMed had confirmed the public offering price at the top end of the desired band, 15,000 KRW, during the demand forecast for domestic and foreign institutional investors.

Based on its core technology, 'Lab-on-a-Chip,' MikobioMed, which can provide customized responses to various types of diseases, has completed the initial public offering process, demonstrating the strength of K-Bio. Amid favorable reviews in the global market, product supply is rapidly increasing, mainly in South American and Asian countries. Recently, the company signed a molecular diagnostic product order contract worth 12 million USD with Argentina, and additional order discussions are ongoing, including with India, raising expectations for further corporate growth after listing.

Kim Sung-woo, CEO of MikobioMed, stated, “The public offering funds will be invested in expanding production facilities and research and development,” expressing his commitment to ensuring the increase in corporate value after listing.

This content was produced with the assistance of AI translation services.